Marked Clinical Improvement in Childhood Disintegrative Disorder Following High-Dose Benzodiazepine Therapy: A Case Report
J. Schulte, I.S. Ribeiro, Ö. Korkmaz, H. Waked, M. Abdallah
Abstract
Childhood disintegrative disorder (CDD) or Heller’s Syndrome is a regressive neurodevelopmental presentation interpreted within the contemporary autism spectrum framework. It is a rare developmental disorder characterised by mostly normal early childhood development followed by significant regression in areas such as communication, social interaction, and motor skills.
We report a case of CDD in a 16-year-old male who was admitted to the emergency child psychiatry department due to aggressive behaviour, loss of language and motor abilities, stool and urine incontinence, and focal epilepsy. After more than 10 years of follow-up in a child neurology department with multiple psychopharmacological trials, the patient was transferred to our child psychiatry department, where the diagnosis of CDD was made. He subsequently showed significant improvement with relatively high doses of benzodiazepines combined with intensive multimodal therapeutic management as the primary treatment.
Keywords
Heller Syndrome, Childhood Disintegrative Disorder (CDD), Pervasive Developmental Disorder (PDD), Autism
Introduction
Childhood Disintegrative Disorder (CDD), or Heller Syndrome, is a very rare developmental disorder with an estimated prevalence of 1.7 per 100,000 [1]. An earlier estimate from the U.S. state of North Dakota is approximately 1.2 per 100,000 [2].
The disorder was first described in 1908 by the Austrian educator Theodor Heller as Dementia Infantilis [3]. Since then, it has been referred to as Heller Syndrome, disintegrative psychosis, and Childhood Disintegrative Disorder (CDD). In the ICD-10, the syndrome is listed under code F84.3, “Other childhood disintegrative disorder.”
The disorder is defined by a period of typical development followed by a “definite loss of previously acquired skills in several areas of development over the course of a few months” [4]. According to diagnostic criteria, children with Heller Syndrome typically lose interest in their environment, exhibit stereotyped and repetitive motor mannerisms, and show autistic-like abnormalities in social interaction and communication [4].
A comparison of cases of Heller Syndrome (CDD) with autism [5] revealed that patients with Heller Syndrome had the lowest IQs, were more often mute, and had a poorer prognosis.
Heller Syndrome affects males more frequently, with a ratio of four males to one female [6]. Volkmar et al report that the mean age of onset ranges from 24 to 42 months [5], while Volkmar reports a mean age of 3.36 years [6] . There are also reports of cases with a significantly later onset, though still within childhood [7]. Furthermore, different onset patterns have been observed: both insidious onset over weeks to months and abrupt onset over days to weeks [6,7]. In some cases, there was a premonitory phase “during which the child became more active, anxious, and restless” [6].
Little is known about the aetiology of Heller Syndrome. In some cases, the onset could be temporally associated with a significant life event—such as the birth of a sibling, which is typical for the age group—or with various medical conditions. However, these associations may simply reflect the family’s attempt to make sense of the child’s sudden regression [7]. There is a “pattern of EEG abnormalities and seizure disorder” [6]. Mouridsen cautioned professionals to be particularly mindful of possible diagnosable neurological disorders when the child is older at the time of diagnosis [8].
Case Report
First A 16-year-old male patient was admitted to our hospital through a child neurology department in a neighbouring city, where he had been receiving treatment for focal epilepsy. The reason for the patient’s transfer to our clinic was progressively worsening auto-aggressive behaviour, as well as aggression toward clinical staff and family members. The neurology department reported that the aggression showed no clear pattern and was resistant to several medications.
At the time of admission, the patient was receiving three antipsychotics (Pipamperone 120 mg daily, Levomepromazine 75 mg daily, and Paliperidone 50 mg intramuscularly once every three weeks), Diazepam 4.5 mg daily, two antiepileptic medications (Lamotrigine 300 mg twice daily and Lacosamide 300 mg twice daily), and one alpha-2 adrenoceptor agonist (Clonidine 75 µg ½ tablet three times daily).
The patient is the first child of a mother who was 24 years old and a father who was 33 years old at the time of his birth. The pregnancy was mostly normal, though episodes of bleeding were reported. The mother denied the use of alcohol, nicotine, or medications during pregnancy. Birth was spontaneous and unremarkable. The patient was breastfed until two years of age. Complementary feeding began with pureed foods at four months and solid foods at six months.
The parents reported noticing mildly delayed development, particularly in speech and comprehension, starting after the age of two. The patient was able to crawl and walk before 18 months of age. He formed three-word sentences before age two and achieved daytime and night time continence before age three.
According to the parental report, the patient’s first abnormalities appeared at age four, when he developed urinary and faecal incontinence, followed by the first seizure episodes. More recently, his expressive and receptive language abilities declined drastically, leaving him able to repeat only three to four words (“hello,” “goodbye,” “food”).
The patient was first admitted to a child neurology clinic at age six. Comprehensive neurological and radiological investigations—including blood tests, cranial MRI, and genetic testing—were unremarkable. Various antiepileptic medications were trialled until a beneficial therapeutic effect was achieved with the combination of Lacosamide and Lamotrigine.
Upon admission to our intensive child psychiatric unit, the patient required placement in a time-out room due to severe aggression toward himself and others. Subsequently, he required five- to seven-point mechanical restraints by court order. To objectively assess behaviour and functioning, we implemented the NOSIE-30 scale, an instrument with established validity, reliability, and sensitivity to change [9]. The scale consists of 30 items rated on a five-point scale, based on behaviour observed during the preceding three days, completed independently by two informants. The items form six subscales: Social Competence, Social Interest, Personal Neatness, Irritability, Manifest Psychosis, and Retardation (Inactivity), from which Total Positive, Total Negative, and Total Patient Assets scores can be derived [10]. The patient’s initial total row score was 62.
Intensive multimodal therapy with one-to-one support was initiated but showed no clear improvement. A reduction in two antipsychotics (Pipamperone and Paliperidone) produced minimal benefit. Afterwards, Olanzapine treatment was initiated. The dose was titrated to 15 mg daily, resulting in relatively better clinical outcomes.
To further optimise treatment, we attempted to taper the daily Diazepam dose. Despite slow tapering, the patient developed severe auto-aggressive behaviours requiring repeated physical restraints. Diazepam was therefore replaced with Lorazepam. After adjusting and stabilising the Lorazepam dose at 6 mg daily, we achieved substantial behavioural control. Minimal sedation was observed, and aggressive behaviours decreased markedly. NOSIE-30 ratings demonstrated a 26% overall reduction, with a 36% reduction in Irritability and a 20% reduction in Social Competence and Social Interest.
Discussion
The patient met the diagnostic criteria for Childhood Disintegrative Disorder (CDD) in DSM-5 [11,12], showing loss or regression in all major developmental domains—receptive and expressive language, social or adaptive behaviour, play with peers, motor skills, and previously established bowel and bladder control—after apparently normal development during the first two years of life. In addition to these regressions, he demonstrated abnormal functioning across all required behavioural domains, including impaired nonverbal communication, failure to develop peer relationships, lack of social and emotional reciprocity, inability to initiate or sustain conversation, and restricted, repetitive, and stereotyped behaviors such as repetitive head bobbing. These symptoms could not be better explained by any other general medical condition or diagnosed mental disorder.
At age six, the patient was enrolled in a special-needs school focusing on physical and motor development and was followed regularly by the neurology department. According to parental reports, he exhibited slow but continuous decline in language and motor abilities over time. His most recent symptoms, primarily aggressive behaviors, resulted in school suspension in April 2025.
One major differential diagnosis considered was excited catatonia (EC). Although EC shares several features with the present case—including overlapping symptoms and a good response to high-dose lorazepam—we presented the case at our Mental Health Centre’s Morbidity and Mortality Conference (13). The conference included clinicians from the Clinic for Child and Adolescent Psychiatry, the Clinic for Psychosomatic Medicine and Psychotherapy, and the Clinic of Psychiatry and Psychotherapy.
Following multidisciplinary discussion, the consensus was that the clinical presentation is more consistent with childhood disintegrative disorder (CDD) rather than EC. Excited catatonia is typically characterised by excessive and purposeless motor activity in both the upper and lower limbs (hyperkinesis), restlessness, stereotypies, impulsivity, frenzy, and combativeness (14). In contrast, the motor activity observed in our case was more global and largely purposeful. In addition, the loss of major developmental domains persisted even after a period of clinical stabilisation.
A major challenge in this case was the delayed diagnosis. Although symptom deterioration began early and pediatric neurological care was initiated at age six, psychiatric diagnosis and treatment did not begin until ten years later. This delay may reflect unfamiliarity with the disorder and the absence of established treatment guidelines.
Another concern was psychopharmacological polypharmacy. The patient received benzodiazepines alongside antipsychotics and antiepileptics. However, concerns about potential drug interactions and serious adverse effects—such as severe sedation, respiratory depression, or paradoxical disinhibition—did not arise. A follow-up evaluation of the patient in our acute ward 12 weeks later showed stable behavior, with almost no use of physical restraints during the preceding eight weeks.
Conclusion
We report a case of CDD with progressive regressive behaviours that did not respond to multiple antipsychotic trials. Significant improvement was achieved through a relatively high dose of benzodiazepine (Lorazepam 6 mg daily), allowing the patient to attend one hour of schooling and expand his spoken vocabulary. The CDD occurred alongside focal epilepsy, requiring coordinated management across paediatrics, child neurology, and child and adolescent psychiatry.
More than a century after Heller first described this syndrome, little remains known about its aetiology, course, and optimal treatment. No standardised therapeutic guidelines currently exist, although symptom-oriented pharmacological management is feasible. Despite this, caregiver burden remains high. Heller Syndrome appears to be extremely rare, possibly rarer than autism, with which it is often compared. It has been suggested that unfamiliarity, under-recognition, and lack of diagnostic guidelines may contribute to underdiagnosis and low prevalence estimates [8].
Raising public and professional awareness and establishing formal treatment guidelines would support earlier recognition, improve clinical management, and reduce the burden on patients and families.
Disclosure
The authors declared no conflicts of interest. Written consent was obtained from the patient/kin of the patient.
References
[1] Fombonne E. Prevalence of childhood disintegrative disorder. National Autistic Society. 2002;6(2):149-57. doi:10.1177/1362361302006002002.
[2] Burd L, Fisher W, Kerbeshian J, et al. A prevalence study of pervasive developmental disorders in North Dakota. J Am Acad Child Adolesc Psychiatry. 1987;26(5):700-3. doi:10.1097/00004583-198709000-00014.
[3] Westphal A, Schelinski S, Volkmar F, Pelphrey K. Revisiting regression in autism: Heller’s dementia infantilis. J Autism Dev Disord. 2013;43:265-71. doi:10.1007/s10803-012-1559-z.
[4] World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992. Available from: https://icd.who.int/browse10/2019/en#/F84.3.
[5] Volkmar FR, Cohen DJ. Disintegrative disorder or “late onset” autism. J Child Psychol Psychiatry. 1989;30(5):717-24. doi:10.1111/j.1469-7610.1989.tb00784.x.
[6] Volkmar FR. Childhood disintegrative disorder: issues for DSM-IV. J Autism Dev Disord. 1992;22(4):625-42. doi:10.1007/BF01046331.
[7] Di Vara S, Guerrera S, Valeri G, Vicari S. Later onset of childhood disintegrative disorder (CDD): a case report. Neurocase. 2022;28(4):369-74. doi:10.1080/13554794.2022.2130804.
[8] Mouridsen SE. Childhood disintegrative disorder. Brain Dev. 2003;25(4):225-8. doi:10.1016/S0387-7604(02)00228-0.
[9] Honigfeld G. NOSIE-30: history and current status of its use in pharmacopsychiatric research. Mod Probl Pharmacopsychiatry. 1974;7:238-63. doi:10.1159/000395079. PMID: 4606856.
[10] Malony NE. Patterns of psychiatric patients’ perceptions of hospitalisation [Dissertation]. Burnaby (BC): Simon Fraser University; 1986.
Rest of the references and appendices are available on request
About the authors
Jule Schulte is based at the Department of Psychology, University of Siegen, Siegen, NRW, Germany.
Isadora Silva Ribeiro, Özge Korkmaz, Hnadi Waked & Morsi Abdallah are based at the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Klinikum Lüdenscheid, Märkische Hospitals, Lüdenscheid, NRW, Germany.
Morsi Abdallah is affiliated with the University of West Virginia Medical School, Morgantown, WV, USA